Dr. Shen is the President and CEO of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. He went on to obtain a Master's degree in Immunology from the National Institute for Food and Durg Control in 1995. In 2003, Dr. Shen received his Ph.D. degree in Immunology from the University of Massachusetts School of Medicine before founding Biocytogen in 2009 with a vision to become a global leader of new drugs by developing a complete antibody drug R&D system that covers target validation, large-scale production of fully human antibodies drugs, efficacy evaluation using different animal models, IND application and multi-regional clinical trials.
Ph.D. degree from the Max Planck Institute for Biophysical Chemistry, University of Göttingen, Germany. From December 2003 to December 2004, served as a postdoctoral researcher at the Max Planck Institute for Biophysical Chemistry. From July 2006 to November 2013, worked as a researcher at Boston Children's Hospital and Harvard Medical School. From October 2013 to December 2020, held the position of Director of Research and Development and Marketing at Biocytogen. Since December 2020, currently serving as Deputy General Manager.
Ph.D. degree from the University of Connecticut. In June 2008, served as a postdoctoral researcher at New York University. In July 2014, became an Assistant Professor at the Medical University of South Carolina. From November 2016 to September 2018, served as the Director of Antibody Development at Biocytogen. From September 2018 to November 2020, held the position of CSO at Biocytogen. Since December 2020, currently serving as Deputy General Manager.
Zhu Yan obtained the inaugural EMBA from the School of Economics and Management, Tsinghua University. With over 10 years of clinical medical practice and nearly 20 years of operational management experience in the biotechnology industry. Zhu Yan possesses a systematic and in-depth understanding of the development patterns within the biopharmaceutical sector. Zhu Yan has accumulated abundant practical experience in areas such as biopharmaceutical research and development, production, quality management processes, and the establishment of management systems, as well as high-tech talent incentive systems. From December 2011 to December 2020, held various positions at Biocytogen, including Assistant to the General Manager and in charge of the Finance Department, as well as Deputy General Manager. Since December 2020, have been serving as the Deputy General Manager.
In 2000, Dr. Yu received his Ph.D. degree in Neurobiology from Sun Yat-sen University of Medical Sciences. Dr. Yu was successively engaged in postdoctoral research at Emory University, Yale University, and Boston Children's Hospital of Harvard University, and served as a scientist and lecturer. In 2006, Dr. Yu joined Alexion Pharmaceuticals, Inc., an American biopharmaceutical company, and successively served as the Senior Scientist, Chief Scientist and Director of Preclinical Drug Research and Development. In 2018, Dr. Yu joined Gemini, a biopharmaceutical company in Boston, USA, responsible for the preclinical drug research and development. In 2020, Dr. Yu joined Biocytogen as the Global Head of Preclinical Pharmacology. Since December 2020, currently serving as Deputy General Manager.
Director of Finance
Master's degree in International Management from Arizona State University.With over twenty years of financial management experience, served as Finance Operations Manager at Cabletron Systems and Senior Finance Manager at ESS Vialta. He has also worked as Finance Director at ABB Xi'an Power Capacitor Co., Chief Financial Officer at KD BlueSky, Chief Financial Officer at Beijing Century Tianle Business Management Company, and Chief Financial Officer at Anji Julong Management Consulting Partnership Enterprise. From April 2020 to December 2020, he was the Chief Financial Officer at Biocytogen. Since December 2020, he has been serving as the Director of Finance at Biocytogen.
Deputy general manager
Master's degree in Science from Nankai University. From August 2010 to February 2014, served as an Investment Manager at China National Chemical Corporation (now known as ChemChina Holdings Co., Ltd.). From February 2014 to September 2015, held the position of Senior Investment Manager at China Hi-Tech Investment Group Corporation (now known as China Investment Corporation High Technology Industry Investment Co., Ltd.). From October 2015 to July 2017, worked as a Senior Investment Manager and Investment Deputy Director at ChinaAMC Asset Management Co., Ltd. From July 2017 to December 2020, served as the Assistant to the Chairman at Biocytogen. Since December 2020, have been serving as the Secretary of the Board of Directors. Since July 2021,have also held the position of Deputy General Manager and Secretary of the Board of Directors.
Director of Pharmacology
Dirui Li received his PhD from College of Veterinary Medicine, China Agricultural University in 2012 (majoring in veterinary biomedicine) and research focused on infection and Immunology & Recombinant Vaccines; Then he did postdoc research at China Agricultural University and Uppsala University, Sweden. In 2016, he returned to China to join Biocytogen Pharmaceuticals（Beijing）Co., Ltd, successively served as Senior Scientist of Gene Editing Department, Manager of Pharmacological Department and Senior Manager of SD Department, currently served as the head of Pharmacology Department（Beijing/Haimen）, and developed the pharmacological platform (biomarker, drug metabolism, toxicological pathology detection platform) for Pharmacology Department.
Senior Director of the Animal Center
Ph.D. degree from China Pharmaceutical University. In 2009, joined Biocytogen and held positions as Molecular Biology Supervisor and Marketing Director. From October 2015 to December 2019, served as a supervisor and Senior Operations Director at Biocytogen in Jiangsu. From January 2020 to December 2020, held the position of Senior Director at the Biocytogen Animal Center. Since December 2020, have been serving as the Senior Director of the Animal Center and Executive Director.
Director of the Gene Editing Department
Dr. Yao received his Ph.D. degree in Pharmaceutical Engineering from Tianjin University in 2012. His research interests include protein interactions, high-throughput screening, and mechanisms of antioxidant signaling pathways. In June 2012, he joined Biocytogen. He has led or participated in the development of EGE technology for efficient gene editing, the establishment of gene editing platform for cell lines, the promotion of laboratory automation, and the work related to the development and application of SUPCE technology. Dr. Yao has nearly ten years of experience in gene editing technology development and animal model development. Since November 2022, have been serving as a Supervisor and Director of the Gene Editing Department at Biocytogen.
Rong ChenMD PhD
CEO and CMO of Eucure Biopharma
Ph.D. degree from the University of Adelaide and Adelaide Royal Hospital. From November 2016 to December 2017, served as the Chief Medical Officer at Phygelius Biotech (China) Co., Ltd.From January 2018 to January 2020, held the position of Chief Medical Officer at Xikang (Wuhan) Biopharmaceutical Co., Ltd. From June 2020 to June 2021, served as the Chief Medical Officer at Shanghai Langhua Biotechnology Co., Ltd. Since June 2021, have been the CEO & CMO of Eucure Pharmaceuticals. Since July 2021, have also held the position of Deputy General Manager at Biocytogen.
COO of Eucure Biopharma
EMBA degree from Peking University. From May 2004 to May 2012, held various positions at EQWei Pharmaceutical Technology (Shanghai) Co., Ltd., including Laboratory Assistant, Project Coordinator, Senior Project Coordinator, Assistant Project Manager, Project Manager, and Business Development Manager. From May 2012 to July 2013, worked as the Preclinical Analytics Manager at IQVIA RDS East Asia Pte Ltd. in the Asia-Pacific region. From July 2013 to July 2014, served as the Deputy Director of Business Development at EQWei Pharmaceutical Technology (Shanghai) Co., Ltd. From September 2014 to August 2018, held positions at Jingding Medical Research and Development (Shanghai) Co., Ltd., including Director of Business Development, Head of China Business Development, and Senior Director of Clinical Operations. From September 2018 to October 2019, served as the head of biologic medicine Center of Aikunwei Pharmaceutical Technology (Shanghai) Co., LTD.Since October 2019, have been serving as the Chief Operating Officer at Eucure Pharmaceuticals. Since December 2020, have also held the position of Deputy General Manager at Biocytogen.
Chief regulatory and strategy officer of Eucure Biopharma
Ph.D. degree from the University of Minnesota, Twin Cities in the United States. From October 2006 to May 2009, served as a Manager at Pfizer, Inc. .From May 2009 to December 2017, worked as a Senior Reviewer at the U.S. Food and Drug Administration (FDA). From January 2018 to December 2018, held the position of Vice President of International Regulatory Affairs at FMD K&L Inc.. Since March 2019, have been serving as the Chief Regulatory and Strategic Officer at Eucure Pharmaceuticals. Since December 2020, have also held the position of Deputy General Manager at Biocytogen.
General Manager of Boston Corp
Ph.D. degree from Albert Einstein College of Medicine. From July 2002 to July 2005, served as the Director of the Mouse Genetic Engineering Laboratory at Harvard Medical School. From July 2005 to December 2009, held positions as Senior Scientist and Chief Scientist at Wyeth Pharmaceuticals Limited, Gene Engineering Laboratory. From January 2010 to December 2013, worked as the Chief Scientist and Project Leader at the Antibody Gene Engineering Laboratory of Pfizer, Inc. From January 2014 to February 2018, served as the Senior Vice President of Research and Development at Beijing Shenogen Pharma Group Ltd. From February 2018 to December 2020, served as the Deputy General Manager of Biocytogen. Since June 2018, have been serving as the General Manager of Boston Corp.